CytomX Therapeutics vs Prelude Therapeutics
CTMX and PRLD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTMX and PRLD compare
CytomX Therapeutics is the larger company, worth 1.5 times as much as Prelude Therapeutics ($464M against $302M).
Prelude Therapeutics grew revenue faster over the last twelve months (220% versus −87.7% for CytomX Therapeutics).
Prelude Therapeutics keeps more of each dollar of sales as profit, with a net margin of −270% compared with −609% at CytomX Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTMX | PRLD |
|---|---|---|
| Size and price | ||
| Market cap | $464M | $302M |
| Share price | $2.13 | $3.78 |
| Change, 1 year | −49.2% | 200% |
| Change, 5 years | −71.0% | −73.9% |
| Beta (5Y) | 1.60 | 1.24 |
| Employees | 69 | 79 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 1 | 1 |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 33.1× | 13.5× (better) |
| P/B | 1.6× (better) | 2.3× |
| FCF yield | −11.0% (better) | −11.0% |
| Fair value | – | $2.16 |
| Margin of safety | – | −74.8% |
| Growth | ||
| Revenue growth (TTM) | −87.7% | 220% (better) |
| Revenue growth, 5Y average | 2.2% | – |
| Net income growth (TTM) | −405% | – |
| EPS growth (TTM) | −215% | – |
| Profitability | ||
| Operating margin | −676% | −301% (better) |
| Net margin | −609% | −270% (better) |
| FCF margin | −364% | −148% (better) |
| Return on equity | −43.6% (better) | −57.7% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.82 (better) | 4.07 |
| Altman Z-score | 0.73 (better) | −2.29 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −52.7% | – |
| Shareholder yield | −52.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 62.2% |
| Held by insiders | 1.5% | 40.5% |
| Insider net buying, 12 months | −$1.2M | $25.0M (better) |
| Short interest, % of float | 21.1% | 8.8% |
Go deeper
- CTMX stock overview
- CTMX income statement
- CTMX valuation and score
- PRLD stock overview
- PRLD income statement
- PRLD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.